

2015 Assessment of Evaluation and Treatment Planning Melanoma of Skin

STUDY PURPOSE: To assess if Stage I Melanoma of Skin cases diagnosed and treated at SRMH have diagnostic work-up and treatment based on NCCN Guidelines.

CoC Cancer Program Requirement: Standard 4.6: Assessment and Evaluation of Treatment Planning: Each year, a physician member of the cancer committee performs a study to assess whether patients within the program are evaluated and treated according to evidence-based national treatment guidelines. The study must determine that the diagnostic evaluation is adequate and the treatment plan is concordant with a recognized guideline.

Physician Member of Cancer Committee to perform study: Ian Anderson, MD

Background:

The study conducted by Cancer Committee this year analyzed the diagnostic and treatment patterns of Melanoma patients compared to the NCCN (National Comprehensive Cancer Network) Version 3.2015.

Study Criteria: Site Specific Sample based on identified need or concern:

Site Specific Sample:	Melanoma of Skin
Accession Year:	2013 and 2014, Class of Case 00-22
Focus on AJCC Clinical Stages:	Stage IA: T1a, N0 M0 Stage IB: T1b, N0M0; T2a, N0 M0

2013 Total cases: Stage I = 6 cases

2014 Total cases: Stage I = 6 cases

Data reviewed for each case included looking at the patient's age, diagnostic workup, clinical stage, and first course of treatment documented in the Cancer Registry (CR) abstract.

Diagnostic Evaluation and Primary Treatment based on NCCN Guideline:

Preliminary workup following a positive biopsy for a suspicious pigmented lesion:

- Pathology Report should contain: Breslow thickness, ulceration, dermal mitotic rate, assessment of deep and peripheral margin status, microsatellitosis, Clark's level, and if pure desmoplasia is present.
- H & P with attention to loco-regional area, draining lymph nodes, and complete skin exam.
- Assessment of melanoma related risk factors: family history of melanoma, prior primary melanoma, and other factors such as atypical moles/dysplastic nevi.
- Routine imaging/lab tests are not recommended
 - Imaging (CT scan, PET/CT, MRI) only to evaluate specific signs or symptoms

Primary Treatment:

- Stage IA and Stage IB: Wide excision with clinical margins based on Breslow thickness
- Stage IA with (0.76-1.00 mm thick, no ulceration, mitotic rate 0 per mm²)⁹: Wide excision plus discuss and consider sentinel node biopsy

2014 SRMH Melanoma Cases: Study Assessment Summary:
Summary of Melanoma Cases for 2014:

A review of all of the melanoma cases for 2014 showed a total of 25 cases of malignant melanoma skin cancer were accessioned by the Santa Rosa Memorial Hospital Cancer Registry. (10) Stage 1, (7) Stage 2, (3) Stage 3, (1) Stage 4 and (4) Unknown Stage. 68% males and 32% females. 100% histologically confirmed diagnoses. Ethnicity: 100% White, (96% White and 4% White/Hispanic). Ages ranged at diagnosis 36 to 94 with median age at diagnosis being 67 years of age.

ANALYTIC CASES: A total of 17 cases were analytic (Class 0 – 22): (6) Stage 1, (5) Stage 2, (3) Stage 3, (0) Stage 4 and (3) Unknown Stage. Analytic, Stage 1a and 1b cases represent 35% of the analytic melanoma cases and are the focus group for this analysis.

DIAGNOSTIC WORKUP:

H&P NCCN RECOMMENDED DATA ITEMS AND SRMH RATES:

<u>Family History of Melanoma</u>	<u>Prior Primary Melanoma</u>	<u>Other Factors Atypical Moles</u>	<u>Complete Skin Exam</u>	<u>Loco-regional Area</u>	<u>Draining Lymph Nodes</u>
8%	67%	0%	0%	100%	50%

PATH REPORT WITH REQUIRED DATA ITEMS:

<u>Breslow Depth/ Thickness</u>	<u>Ulceration</u>	<u>Mitotic Rate</u>	<u>Deep & Periph. Margins</u>	<u>Microsatellitosis</u>	<u>Clark's Level</u>
100%	100%	67%	100%	17%	17%

TREATMENT SUMMARY:

<u>Stage at Dx.</u>	<u>Surgery</u>	<u>Scope of LND</u>
1b	Code 30-Bx.Primary & Exc.	Sentinel node
1b	Code 30-Bx.Primary & Exc.	Not recommend
1b	Code 36-Inc.Bx. & Exc.	Sentinel node
1b	Code 33-Mohs >1cm marg	Pt. declined
1b	Code 31-Shave Bx. & Exc	Not recommend
1a	Code 30-Bx.Primary & Exc.	Not recommend

2013 SRMH Melanoma Cases: Study Assessment Summary:

Summary of Melanoma Cases for 2013:

A review of all of the melanoma cases for 2013 showed a total of 19 cases of malignant melanoma skin cancer were accessioned by the Santa Rosa Memorial Hospital Cancer Registry. (6) Stage1, (3) Stage 2, (6) Stage 3, (1) Stage 4 and (3) Unknown Stage. 47% males and 53% females. 100% histologically confirmed diagnoses. Ethnicity: 100% White. Ages ranged at diagnosis 35 to 92 with median age at diagnosis being 66 years of age.

ANALYTIC CASES: A total of 15 cases were analytic (Class 0 – 22): (6) Stage 1, (3) Stage 2, (5) Stage 3, (1) Stage 4 . Analytic, Stage 1a and 1b cases represent 40% of the analytic melanoma cases and are the focus group for this analysis.

DIAGNOSTIC WORKUP:**H&P NCCN RECOMMENDED DATA ITEMS AND SRMH RATES:**

<u>Family History of Melanoma</u>	<u>Prior Primary Melanoma</u>	<u>Other Factors Atypical Moles</u>	<u>Complete Skin Exam</u>	<u>Loco-regional Area</u>	<u>Draining Lymph Nodes</u>
0%	67%	67%	0%	67%	100%

PATH REPORT WITH REQUIRED DATA ITEMS:

<u>Breslow Depth/ Thickness</u>	<u>Ulceration</u>	<u>Mitotic Rate</u>	<u>Deep & Periph. Margins</u>	<u>Microsatellitosis</u>	<u>Clark's Level</u>
100%	100%	60%	100%	60%	40%

TREATMENT SUMMARY:

<u>Stage at Dx.</u>	<u>Surgery</u>	<u>Scope of LND</u>	<u>Scans</u>
1b	Code 30-Bx.Primary & Exc.	Sentinel node	Lymphangiogram
1b	Code 30-Bx.Primary & Exc.	Sentinel node	Lymphangiogram
1b	Code 30-Bx.Primary & Exc.	Sentinel node	Lymphangiogram
1b	Code 33-Mohs >1cm margin	Sentinel node	Lymphangiogram
1b	Code 46-Exc 1cm< 2cm marg	Sentinel node	Lymphangiogram
1a	Code 35-Mohs <`cm margin	Sentinel node	Lymphangiogram

PRESENTED TO CANCER COMMITTEE: __November 5, 2015__

SANTA ROSA MEMORIAL HOSPITAL - 2014 Primary Site Table

Primary Site	Total	Class		Sex			AJCC Stage			
		A	N/A	M	F	O	I	II	III	IV
All Sites	998	749	249	439	559	59	179	142	103	187
Oral Cavity	24	13	11	18	6	0	0	3	5	10
Tongue	11	5	6	10	1	0	0	0	2	6
Oropharynx	2	1	1	2	0	0	0	0	1	0
Hypopharynx	1	1	0	1	0	0	0	0	0	1
Other	10	6	4	5	5	0	0	3	2	3
Digestive System	177	139	38	103	74	1	13	39	35	39
Esophagus	15	11	4	13	2	0	2	1	2	3
Stomach	15	12	3	8	7	0	0	4	1	5
Colon	54	43	11	28	26	0	3	17	14	13
Rectum	28	20	8	14	14	1	2	5	11	3
Anus/Anal Canal	5	5	0	1	4	0	1	2	0	0
Liver	18	13	5	13	5	0	5	1	2	1
Pancreas	30	24	6	21	9	0	0	6	4	11
Other	12	11	1	5	7	0	0	3	1	3
Respiratory System	158	133	25	62	96	1	22	8	17	63
Larynx	2	2	0	1	1	0	0	0	1	0
Lung/Bronc-Small Cell	19	15	4	7	12	0	1	0	2	7
Lung/Bronc-Non Small Cell	117	104	13	48	69	0	20	7	13	50
Other Bronchus & Lung	20	12	8	6	14	1	1	1	1	6
Blood & Bone Marrow	88	44	44	53	35	0	0	0	0	1
Leukemia	40	24	16	26	14	0	0	0	0	1
Multiple Myeloma	19	10	9	9	10	0	0	0	0	0
Other	29	10	19	18	11	0	0	0	0	0
Connect/Soft Tissue	1	0	1	0	1	0	0	0	0	1
Skin	35	25	10	20	15	3	8	9	4	3
Melanoma	32	22	10	17	15	3	7	9	3	3
Other	3	3	0	3	0	0	1	0	1	0
Breast	197	166	31	2	195	30	85	45	6	11
Female Genital	58	39	19	0	58	0	10	4	16	13
Cervix Uteri	3	1	2	0	3	0	0	0	1	1
Corpus Uteri	16	11	5	0	16	0	6	0	2	4
Ovary	30	20	10	0	30	0	2	3	13	6
Vulva	4	3	1	0	4	0	0	0	0	2
Other	5	4	1	0	5	0	2	1	0	0
Male Genital	62	33	29	62	0	0	5	17	5	14
Prostate	60	31	29	60	0	0	3	17	5	14
Testis	2	2	0	2	0	0	2	0	0	0
Urinary System	63	49	14	45	18	24	13	5	2	9
Bladder	43	38	5	32	11	24	8	5	0	1
Kidney/Renal	20	11	9	13	7	0	5	0	2	8
Brain & Cns	28	22	6	15	13	0	0	0	0	0
Brain (Benign)	1	1	0	0	1	0	0	0	0	0
Brain (Malignant)	11	9	2	8	3	0	0	0	0	0
Other	16	12	4	7	9	0	0	0	0	0
Endocrine	33	30	3	13	20	0	16	4	6	3
Thyroid	32	29	3	12	20	0	16	4	6	3
Other	1	1	0	1	0	0	0	0	0	0
Lymphatic System	51	38	13	33	18	0	7	7	6	17
Hodgkin's Disease	5	5	0	4	1	0	1	1	0	2
Non-Hodgkin's	46	33	13	29	17	0	6	6	6	15
Unknown Primary	15	11	4	8	7	0	0	0	0	0
Other/Ill-Defined	8	7	1	5	3	0	0	1	1	3